FDA & EMA approval to begin human trials in the development of our neurotech platform for designing altered states
Ayuh Ventures Longevity Fund I port co receives both FDA & EMA approval to begin human trials in the development of our neurotech platform for designing altered states: “We don’t need to eliminate the psychoactive effects of psychedelics. We need the ability to choose the effects that are helpful — to transform these largely effective but unpredictable messes of psychoactive effects into a series of precision-targeted psychoactive pro”
“It’s time to move beyond “psychedelics” and begin the precision design of mood, cognition, and perception” This milestone marks the beginning of clinical validation for Mindstate’s advanced neurotech AI platform, Osmanthus, which is designed to meticulously craft new altered states of consciousness. How do you understand the architecture of the mind? “We hope that our drug will become the first line of care, potentially used in combination or by itself, to provide real relief to patients”
Mindstate Design Labs is a clinical-stage biopharmaceutical company focused on developing and commercializing compounds such as a non-toxic variation of MDMA and a more effective variation of psilocybin to precisely design subjective states without off-target effects. They are initially targeting Treatment Resistant PTSD and Treatment Resistant Depression and have a robust pipeline of proprietary, novel states targeting the constructs at the root of intractable mental health disorders.
